--- title: "Whitehawk Therapeutics (WHWK) news: offering" url: "https://aibio.space/companies/whitehawk-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "WHWK offering news: Whitehawk Therapeutics agrees to $87.5 million private placement of stock and warrants. Whitehawk Therapeutics, Inc." --- WHWK Whitehawk Therapeutics, Inc. NASDAQ · United States # Whitehawk Therapeutics (WHWK) news WHWK offering news Financings · 2026-05-13 ## [Whitehawk Therapeutics agrees to $87.5 million private placement of stock and warrants](https://aibio.space/news/whitehawk-therapeutics-agrees-87-5-million-private-placement-stock/) Whitehawk agreed to sell 4,330,866 shares at $3.92 and 17,991,021 pre-funded warrants in a PIPE financing. The company expects gross proceeds of about $87.5 million and a May 14, 2026 closing. ## Latest Whitehawk Therapeutics news 1. 2025-03-26 Mergers [Whitehawk Therapeutics (formerly Aadi Bioscience) completes $102.4 million sale of Aadi Subsidiary](https://aibio.space/news/whitehawk-therapeutics-formerly-aadi-bioscience-completes-102-4/) KAKEN INVESTMENTS INC. paid $102.4 million in cash at closing on March 25, 2025, after purchase price adjustments, for 100% of the stock of Aadi Subsidiary, Inc. 2. 2025-03-26 Mergers [Whitehawk Therapeutics completes sale of Aadi Subsidiary to Kaken for $102.4 million](https://aibio.space/news/whitehawk-therapeutics-completes-sale-aadi-subsidiary-kaken-102-4/) The buyer paid the cash on closing after purchase price adjustments. The deal was signed on December 19, 2024 under the company's former name, Aadi Bioscience. 3. 2025-03-04 Financings [Aadi Bioscience (now Whitehawk Therapeutics) closes $100 million private placement](https://aibio.space/news/aadi-bioscience-now-whitehawk-therapeutics-closes-100-million-private/) Aadi Bioscience closed a private placement of about $100 million on March 4, 2025, selling 21,592,000 shares at $2.40 and pre-funded warrants for 20,076,500 more shares. The company says the money, with the FYARRO sale, should fund operations into 2028. 4. 2025-01-21 Mergers [Aadi Bioscience (now Whitehawk Therapeutics) seeks vote on $100 million FYARRO sale](https://aibio.space/news/aadi-bioscience-now-whitehawk-therapeutics-seeks-vote-100-million/) Aadi Bioscience's preliminary proxy, filed January 21, 2025, asks holders to approve a $100 million cash sale of its FYARRO business to Kaken and a private placement of 21,592,000 shares at $2.40 each. The meeting date is still blank in that filing. ## Whitehawk Therapeutics at a glance - **Ticker**: WHWK - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $190.0 million ### Related companies - [Exicure](https://aibio.space/companies/exicure/) NASDAQ: XCUR - [OSR Health](https://aibio.space/companies/osr-health/) OTC: OSRH - [United Therapeutics](https://aibio.space/companies/united-therapeutics/) NASDAQ: UTHR - [Agenus](https://aibio.space/companies/agenus/) NASDAQ: AGEN - [HCW Biologics](https://aibio.space/companies/hcw-biologics/) NASDAQ: HCWB - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD - [Galectin Therapeutics](https://aibio.space/companies/galectin-therapeutics/) NASDAQ: GALT - [Vaxcyte](https://aibio.space/companies/vaxcyte/) NASDAQ: PCVX ### Also on NASDAQ - [Inhibrx Biosciences](https://aibio.space/companies/inhibrx-biosciences/) INBX - [Apollomics](https://aibio.space/companies/apollomics/) APLM - [DarioHealth](https://aibio.space/companies/dariohealth/) DRIO - [Jaguar Health](https://aibio.space/companies/jaguar-health/) JAGX - [Creative Medical Technology Holdings](https://aibio.space/companies/creative-medical-technology/) CELZ - [Alumis](https://aibio.space/companies/alumis/) ALMS ## Whitehawk Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$7.1 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | [$26.0 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | | Research and development | [$91.0 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | [$51.0 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | | Net income (loss) | [-$20.6 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | [-$63.7 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | | Cash from operations | [-$97.4 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | [-$59.5 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | | Cash and equivalents | [$37.6 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526337933/) | [$28.7 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | | Short-term investments | [$108.1 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526337933/) | [$18.6 million](https://www.sec.gov/Archives/edgar/data/1422142/000119312526104158/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $85.2 million, plus short-term investments of $104.7 million, $190.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Whitehawk Therapeutics Has Whitehawk Therapeutics raised money recently? Our latest story on this, dated May 13, 2026: "Whitehawk Therapeutics agrees to $87.5 million private placement of stock and warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/whitehawk-therapeutics-agrees-87-5-million-private-placement-stock/). What is the ticker symbol of Whitehawk Therapeutics? Whitehawk Therapeutics, Inc. trades under the ticker WHWK on NASDAQ. Where is Whitehawk Therapeutics listed? Whitehawk Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:3350; LS:A3CSR9. What is the SEC CIK of Whitehawk Therapeutics? The SEC Central Index Key (CIK) for Whitehawk Therapeutics, Inc. is 1422142. Its filings are on SEC EDGAR. How many shares does Whitehawk Therapeutics have outstanding? 57,009,010 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Whitehawk Therapeutics listed under? Our directory records Whitehawk Therapeutics, Inc. under United States. What does Whitehawk Therapeutics do? Our directory classifies Whitehawk Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Whitehawk Therapeutics? The ISIN recorded for Whitehawk Therapeutics, Inc. is US00032Q1040. Does aibio.space cover Whitehawk Therapeutics? aibio.space lists Whitehawk Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Whitehawk Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Whitehawk Therapeutics's revenue last year? $7.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Whitehawk Therapeutics profitable? Whitehawk Therapeutics, Inc. reported a net loss of $20.6 million for the fiscal year ended Dec 31, 2025, and used $97.4 million of cash in operations, per its annual report to the SEC. How much does Whitehawk Therapeutics spend on research and development? $91.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Whitehawk Therapeutics have? $190.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Whitehawk Therapeutics (WHWK) stock news? Our latest story on Whitehawk Therapeutics, dated May 13, 2026: "Whitehawk Therapeutics agrees to $87.5 million private placement of stock and warrants". Whitehawk agreed to sell 4,330,866 shares at $3.92 and 17,991,021 pre-funded warrants in a PIPE financing. The company expects gross proceeds of about $87.5 million and a May 14, 2026 closing. [Source](https://aibio.space/news/whitehawk-therapeutics-agrees-87-5-million-private-placement-stock/). ## Investor discussion: Whitehawk Therapeutics Members talk about Whitehawk Therapeutics (WHWK). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Whitehawk Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1422142/000119312526220656/d854431dex991.htm) 2. 2025-04-25 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1422142/000119312525097064/d936092d424b5.htm) 3. 2025-03-26 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1422142/000119312525063253/d937606d8k.htm) 4. 2025-03-04 Financings Reported a financing. SEC Form 8-K (Items 1.01,5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1422142/000119312525045605/d892218dex991.htm) 5. 2025-01-21 Mergers Filed documents for a merger or acquisition. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1422142/000119312525009599/d923919dprem14a.htm) 6. 2024-12-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/d891246dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:WHWK on TradingView](https://www.tradingview.com/symbols/NASDAQ-WHWK/). ## SEC filings and registration - **SEC name**: Whitehawk Therapeutics, Inc. - **CIK**: 1422142 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: WHWK (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2 HEADQUARTERS PLAZA, MORRISTOWN, NJ, 07960 - **Phone**: 551-321-2234 - **Shares outstanding**: 57,009,010 as of 2026-08-03 (10-Q filed 2026-08-06) - **Former names**: Aadi Bioscience, Inc.; Aerpio Pharmaceuticals, Inc.; ZETA ACQUISITION CORP II ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1422142/000119312526388010/d160342d8k.htm) filed 2026-09-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1422142/000119312526337933/whwk-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/whwk-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1422142/000119312526269493/whwk-20260611.htm) filed 2026-06-12 - [S-3](https://www.sec.gov/Archives/edgar/data/1422142/000119312526248349/d155546ds3.htm) filed 2026-05-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1422142/000119312526234890/d32951d8k.htm) filed 2026-05-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1422142/000119312526220656/d854431d8k.htm) filed 2026-05-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1422142/000119312526212075/whwk-20260331.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001422142), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Whitehawk Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker WHWK, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Whitehawk Therapeutics, Inc. - **Ticker**: WHWK - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US00032Q1040 - **Other listed symbols**: GETTEX:3350; LS:A3CSR9 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-WHWK/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/whitehawk-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Whitehawk Therapeutics (WHWK) news: offering", 2026-10-31, https://aibio.space/companies/whitehawk-therapeutics/